Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)


UCAM (participant 2) is responsible for CIMBA. CIMBA is an international consortium evaluating potential genetic modifiers of cancer risk in BRCA1 and BRCA2 carriers (http://www.srl.cam.ac.uk/consortia/cimba/index.html). Over 20,000 carriers from 35 centres have been enrolled, about 50% of whom are affected with breast cancer and 10% with ovarian cancer.

http://www.srl.cam.ac.uk/consortia/cimba/index.html

Additional information